Aptose Biosciences (APTO) EGM 2024 summary
Event summary combining transcript, slides, and related documents.
EGM 2024 summary
22 Jan, 2026Opening remarks and agenda
Meeting was properly constituted, with secretary and scrutineer appointed, and confirmation of notice and quorum established.
Shareholders were reminded of their rights to address motions and the process for submitting questions.
Specific resolutions to be voted on
Authorization sought for issuance of common shares underlying certain warrants, in compliance with Nasdaq Listing Rule 5635(d).
Approval requested to adjourn the meeting if necessary to solicit additional proxies.
Shareholder proposals specific to EGM
No additional proposals or other business were brought forward by shareholders or proxy holders.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Aptose Biosciences
- Triplet therapy with tuspetinib, venetoclax, and azacitidine delivers high remission and MRD-negativity rates in AML.APTO
Study update presentation - Tuspetinib triplet therapy shows early promise for newly diagnosed AML, advancing toward pivotal trials.APTOCorporate presentation
- Tuspetinib targets AML resistance, showing broad efficacy and safety as a new frontline triplet therapy.APTOCorporate presentation
- Tuspetinib advances in AML trials, but urgent funding and going concern risks persist.APTOQ1 2026
- 2025 net loss was $25.5M; liquidity depends on Hanmi funding and pending acquisition.APTOQ4 2025
- Board unanimously recommends approval of Hanmi’s C$2.41/share cash acquisition; insolvency risk if not approved.APTOProxy Filing
- Board recommends approval of C$2.41/share cash acquisition, offering a 28% premium.APTOProxy Filing
- Board recommends approval of Hanmi's C$2.41/share cash acquisition, offering a 28% premium.APTOProxy Filing
- Triplet therapy delivers broad, durable AML remissions with strong safety and pivotal trials ahead.APTOBloom Burton & Co. Healthcare Investor Conference 2025